- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Chewable Compound Reduces Post-Meal Blood Glucose in Diabetes Patients
Carbohydrate-based drug completes phase II trial (September 4)
Positive results have been reported from a phase II study that evaluated the safety and efficacy of PAZ320 (Boston Therapeutics), a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. The study was published in Endocrine Practice.
PAZ320 was evaluated in 24 patients aged 18 to 75 years with type 2 diabetes, a body mass index (BMI) of 25 to 40 kg/m2, and hemoglobin A1c (HbA1c) of ≤ 9%. HbA1c is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months.
Forty-five percent of patients responded with a 40% reduction in post-meal glucose in the blood compared with baseline in a dose-dependent manner. In addition, the drug appeared to work regardless of concurrent diabetes medications.
There was no severe hypoglycemia, and gastrointestinal side effects were mild.
PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. The drug is taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.
Source: Boston Therapeutics; September 4, 2013.